Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
22 Juin 2023 - 12:30PM
Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a
clinical-stage immuno-oncology company committed to giving patients
back their innate ability to fight cancer, today announced the
appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory
Board. Dr. Ulmer-Eilfort’s appointment was approved during the
Annual General Meeting of Shareholders which took place on June 21,
2023.
“We are delighted to announce the appointment of
Dr. Ulmer-Eilfort to our Supervisory Board,” said Dr. Thomas Hecht,
Chairman of Affimed’s Supervisory Board. “Constanze brings a wealth
of legal expertise and a deep understanding of the biotech and
healthcare industries, making her an invaluable addition to our
team. With her extensive background, we expect Constanze will
provide critical insights and guidance to the Company on matters
related to corporate governance, corporate strategy, compliance and
ESG, among others.”
Dr. Ulmer-Eilfort is a partner at the law firm
Peters, Schönberger & Partner, an interdisciplinary law and
advisory firm located in Munich, Germany, a role she has held since
2022. Prior to that, Dr. Ulmer-Eilfort worked at Baker
McKenzie serving in several roles, including as partner from 1998
to 2021, Member of the Global Executive Committee from 2017 to
2021, and as Managing Partner of the German and Austrian offices
from 2012 to 2017.
Since 2021, Dr. Ulmer-Eilfort has served as
member of the supervisory board of Evotec SE, a Hamburg-based,
publicly listed drug discovery and development company. She also
serves as Chair of the Advisory Committee at Smart4Diagnostics
GmbH, a healthcare start-up based in Munich. Since 2022, Dr.
Ulmer-Eilfort has also served as a member of the board of Proxygen
GmbH, a Vienna based biotech company developing and commercializing
molecular glue degraders, and is an advisor to the management board
of Artidis AG, a Basel healthcare company developing a technology
platform for the rapid diagnosis of cancer.
Dr. Ulmer-Eilfort holds a law degree from
the University of Munich, a Masters of Law degree from the
University of Pennsylvania Law School, and a doctorate degree in
law from the University of Berlin.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer by actualizing the untapped
potential of the innate immune system. The Company’s proprietary
ROCK® platform enables a tumor-targeted approach to recognize and
kill a range of hematologic and solid tumors, enabling a broad
pipeline of wholly-owned and partnered single agent and combination
therapy programs. The ROCK® platform predictably generates
customized innate cell engager (ICE®) molecules, which use
patients’ immune cells to destroy tumor cells. This innovative
approach enabled Affimed to become the first company with a
clinical-stage ICE®. Headquartered in Heidelberg, Germany, with
offices in New York, NY, Affimed is led by an experienced team of
biotechnology and pharmaceutical leaders united by a bold vision to
stop cancer from ever derailing patients’ lives. For more about the
Company’s people, pipeline and partners, please visit:
www.affimed.com.
Forward-Looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Actual results may differ materially from the results
anticipated by the Company’s forward-looking statements due to
certain risks, uncertainties and other factors described under the
heading “Risk Factors” in Affimed’s filings with the SEC. Given
these risks, uncertainties, and other factors, you should not place
undue reliance on these forward-looking statements, and the Company
assumes no obligation to update these forward-looking statements,
even if new information becomes available in the future.
Investor Relations Contact
Alexander FudukidisDirector, Investor RelationsE-Mail:
a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Affimed NV (NASDAQ:AFMD)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024